Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PVLA Palvella Therapeutics

Market Closed 10-09 16:00:00 EDT

138.77

+7.43

+5.66%

盘后138.77

+0.000.00%

18:57 EDT

High139.86	Low128.80	Vol174.04K
Open130.70	D1 Closing131.34	Amplitude8.42%
Mkt Cap2.00B	Tradable Cap1.17B	Total Shares14.41M
T/O23.85M	T/O Rate2.07%	Tradable Shares8.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":138.77,"timestamp":1791576000000,"preClose":131.34,"halted":0,"volume":174040,"hourTrading":{"tag":"盘后","latestPrice":138.77,"preClose":138.77,"latestTime":"18:57 EDT","volume":2040,"amount":283078.15,"timestamp":1791586647528,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.05657073245012949,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Market Closed","change":7.43,"latestTime":"10-09 16:00:00 EDT","open":130.7,"high":139.86,"low":128.8,"amount":23853619.5704,"amplitude":0.084209,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":131.34,"preHourTrading":{"tag":"盘前","latestPrice":131.27,"preClose":131.34,"latestTime":"05:24 EDT","volume":40,"amount":5251.9704,"timestamp":1791537859534,"change":-0.07,"changeRate":-0.000533,"amplitude":0.000228},"postHourTrading":{"tag":"盘后","latestPrice":138.77,"preClose":138.77,"latestTime":"18:57 EDT","volume":2040,"amount":283078.15,"timestamp":1791586647528,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7486808608989352,"impliedVol":0.4733,"impliedVolPercentile":0.0717},"requestUrl":"/m/hq/s/PVLA","defaultTab":"news","newsList":[{"id":"2673506888","title":"Palvella Therapeutics management to meet with Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2673506888","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673506888?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:25","pubTimestamp":1791307551,"startTime":"0","endTime":"0","summary":"Meeting to be held in Boston on October 6 hosted by Truist. Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-management-to-meet-with-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-management-to-meet-with-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234701","title":"Palvella receives third year of grant funding from FDA for QTORIN","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234701?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:50","pubTimestamp":1790596216,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced that the Company has received a third year of grant funding from the FDA Office of Orphan Products Developme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-receives-third-year-of-grant-funding-from-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-receives-third-year-of-grant-funding-from-fda-for-qtorin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4585","LABU","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670423109","title":"FDA Awards Palvella Third-Year Orphan Grant Funding for Qtorin Rapamycin Phase 3 SELVA Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670423109","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670423109?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595023,"startTime":"0","endTime":"0","summary":"FDA awards Palvella third-year orphan grant funding for QTORIN rapamycin Phase 3 SELVA trialPalvella Therapeutics received a third year of FDA Orphan Products Development grant funding for its Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLbNLRMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","BK4588","BK4585","IE00B3QW5Z07.USD","BCDF","IE00BN0W2V16.EUR","NDAQ","PVLA","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014005.SGD","BK4139","SG9999014039.USD","BK4112","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670310382","title":"U.S. Food and Drug Administration Awards Additional Funding for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2670310382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670310382?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595017,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668978038","title":"Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $656,426.82","url":"https://stock-news.laohu8.com/highlight/detail?id=2668978038","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668978038?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761951,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $656,426.82Palvella Therapeutics COO Kathleen Goin exercised stock options for 4,302 common shares on Sep. 16, 2026.Option","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL8TSKrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $656,426.82","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667675633","title":"Palvella Therapeutics Director George M. Jenkins Disposes of USD 4.15 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2667675633","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667675633?lang=en_us&edition=fundamental","pubTime":"2026-09-16 09:15","pubTimestamp":1789521359,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director George M. Jenkins disposes of USD 4.15 million in common sharesPalvella Therapeutics director George M. Jenkins sold 27,500 common shares on Sep. 11-15.Sales priced betw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL5T4hTy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics Director George M. Jenkins Disposes of USD 4.15 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594181","title":"Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594181","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594181?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:55","pubTimestamp":1789052115,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Palvella Therapeutics today and set a price target of $240.00. Suvannavejh c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058059","title":"Palvella Therapeutics Names Pediatric Dermatologist James Treat Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666058059?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953570,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics names pediatric dermatologist James Treat chief medical officerPalvella Therapeutics appointed James R. Treat as chief medical officer, effective Dec. 21, 2026.Treat most recentl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL5Rk3kQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","PVLA","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458037","title":"Palvella Therapeutics Appoints James R. Treat, M.d., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458037?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:30","pubTimestamp":1788953401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA9H1DXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665357033","title":"Palvella Therapeutics Director Makes Eye-Catching Insider Move in Latest Stock Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2665357033","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665357033?lang=en_us&edition=fundamental","pubTime":"2026-09-05 10:06","pubTimestamp":1788574019,"startTime":"0","endTime":"0","summary":"New insider activity at Palvella Therapeutics ( ($PVLA) ) has taken place on September 4, 2026. Director Christopher P. Kiritsy of Palvella Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/palvella-therapeutics-director-makes-eye-catching-insider-move-in-latest-stock-transaction-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/palvella-therapeutics-director-makes-eye-catching-insider-move-in-latest-stock-transaction-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359285","title":"Palvella Therapeutics Director Christopher P. Kiritsy Disposes of 313 Common Shares for $49,141","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359285","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665359285?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:06","pubTimestamp":1788552360,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director Christopher P. Kiritsy disposes of 313 common shares for $49,141Director Christopher P. Kiritsy cut his Palvella Therapeutics stake to 250 shares on Sep. 2, 2026.Sold 31","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL8JbKBC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Palvella Therapeutics Director Christopher P. Kiritsy Disposes of 313 Common Shares for $49,141","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664148816","title":"Palvella Therapeutics CEO to Speak at Cantor Global Healthcare Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664148816","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664148816?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:30","pubTimestamp":1788348651,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics CEO to speak at Cantor Global Healthcare Conference 2026Palvella Therapeutics CEO Wes Kaupinen will join a fireside chat at the Cantor Global Healthcare Conference on Sept. 9, 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLb3RZXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0314104364.USD","BK4585","LU2095319765.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BQXX3D17.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","SG9999014039.USD","PVLA","SG9999014005.SGD","BK4112","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BCDF","SG9999014013.SGD","IE00BGHQF748.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664554819","title":"Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664554819","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664554819?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:30","pubTimestamp":1788348600,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355020/0/en/palvella-therapeutics-to-participate-in-upcoming-healthcare-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LU0029874061.USD","BK4588","LABU","BK4139","XLV","PVLA","BK4585","BK4581","HCSG","BK4137","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881570","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881570?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:30","pubTimestamp":1788222626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA), Protagonist Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4588","BK4137","LABU","BK4581","LU0128526141.USD","PVLA","LU0029874061.USD","BK4585","XLV","HCSG","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663207065","title":"Palvella Completes Rolling FDA NDA Submission for Qtorin Rapamycin in Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2663207065","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663207065?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:31","pubTimestamp":1788175892,"startTime":"0","endTime":"0","summary":"Palvella completes rolling FDA NDA submission for QTORIN rapamycin in microcystic lymphatic malformationsPalvella Therapeutics completed a rolling NDA submission to the FDA for QTORIN 3.9% rapamycin g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL81tTRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BQXX3F31.USD","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","NDAQ","PVLA","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","BCDF","LU2210150020.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663607037","title":"Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2663607037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663607037?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUABMGH4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070325","title":"Palvella Therapeutics - Accelerating U.S. Launch Readiness for Potential Qtorin Rapamycin Launch in H1 2027 if Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070325?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUABMGH4Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661740234","title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2661740234","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661740234?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:06","pubTimestamp":1787256381,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41Palvella Therapeutics COO Kathleen Goin exercised stock options on Aug. 19, 2026, acquiring 4,302 common sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4yvj0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521017","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521017?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:00","pubTimestamp":1785952826,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA) and Lifecore Biomedical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4121","BK4212","LFCR","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657654223","title":"Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657654223","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657654223?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Aug.  05, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339219/0/en/Palvella-Therapeutics-to-Participate-in-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":0.0476},{"period":"1month","weight":-0.0831},{"period":"3month","weight":-0.0414},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.9799},{"period":"ytd","weight":0.3258}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.069248},{"month":2,"riseRate":0.545455,"avgChangeRate":0.088954},{"month":3,"riseRate":0.454545,"avgChangeRate":0.004194},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.071975},{"month":5,"riseRate":0.454545,"avgChangeRate":0.145935},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.054496},{"month":7,"riseRate":0.666667,"avgChangeRate":0.148037},{"month":8,"riseRate":0.666667,"avgChangeRate":0.116281},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.090932},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.045623},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.051298}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}